1. Guidelines for the risk assessment of new synthetic drugs. European monitoring centre for drugs and drug addiction;EMCDDA,1999
2. Guideline on the non-clinical investigation of the dependence potential of medicinal products;EMEA,2006
3. ICH harmonised tripartite guideline, guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, M3(R2);International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use,2009
4. Guidance for industry. Assessment of abuse potential of drugs;U.S. Department of Health and Human Services, Food and Drug Administration,2010
5. Single convention on narcotic drugs. As amended by the 1972 protocol amending the single convention on narcotic drugs (1961);United Nations International Narcotic Control Board [INCB],1961